Features

•Covers research and clinical application of molecular therapeutic biomarkers for use in oncology and cancer research, including aspects from biology, various evolving and established diagnostic methodologies, and clinical applications
•Includes contributions from many internationally recognized experts and leaders in their specialized fields of oncology, pathology, biostatistics, pharmacology, molecular biology, and translational as well as clinical cancer research
•Provides sufficient chapters on the fundamentals of the field for students and new scientists


Summary


In this volume, a team of internationally recognized experts provide an in-depth description of therapeutic biomarkers across a broad area of cancer research and oncology. With a wealth of information to specific therapies, each chapter focuses on a class of targeted chemotherapy agents. The book describes established and evolving diagnostic tests for therapeutic biomarkers that predict benefit, response, resistance, or drug side effects from specific therapeutic interventions. This volume is an essential handbook for health professionals and scientists researching current applicable biomarkers in oncology.

Overview: Therapeutic Biomarkers in Cancer, Sherry X. Yang and Janet E. Dancey
Statistical Considerations in the Development and Evaluation of Therapeutic Biomarkers in Cancer, Lisa M. McShane, Edward L. Korn and Boris Freidlin
Role of Biomarkers in Clinical Development of New Cancer Therapies, Helen X. Chen
HER2 as a Prognostic and Predictive Biomarker in Cancer, Suparna Wedam and Stan Lipkowitz
Hormone Receptors and Endocrine Therapy in Breast Cancer, Chia C. Portera and Sherry X. Yang
Predictive Biomarkers for Epidermal Growth Factor Receptor (EGFR) Agents in Non-Small Cell Lung Cancer, John Hilton, Penelope A. Bradbury, and Janet E. Dancey
Markers of Sensitivity and Resistance to EGFR Inhibitors in Colorectal Cancer, Jose G. Monzon and Janet E. Dancey
Targeting BCR-ABL for Molecular Therapy of Chronic Myelogenous Leukemia, Shamudheen Rafiyath, Guoqing Wei, and Delong Liu
Gastrointestinal Stromal Tumors (GISTs): From Molecular Pathogenesis to Therapy, Joaquina Baranda, Rashna Madan and Andrew K. Godwin
PML/RARa Fusion Gene and Response to Retinoic Acid and Arsenic Trioxide Treatment, Alicja Gruszka and Myriam Alcalay
Dihydropyrimidine Dehydrogenase Deficiency and 5-Fluouracil Toxicity, Eva Gross and André B. P. van Kuilenburg
UGT1A1 Polymorphisms and Mutations Lead to Irinotecan-Induced Toxicity, Kellie Reece and William D. Figg
The 21-Gene Recurrence Score and Benefit of Chemotherapy in Estrogen Receptor-Positive Breast Cancer, Petra Rietchel and Joseph A. Sparano
MammaPrint for Individualized Recurrence Risk Assessment and Treatment Recommendations for Early-Stage Breast Cancer Patients, Sonal J. Desai and Tianhong Li
BRCA mutation and PARP Inhibitors, Marcie K. Weil, Shivaani Kummar, James H. Doroshow, and Alice P. Chen
EML4-ALK Fusion Gene and Therapy with ALK-targeted Agents in Non-Small Cell Lung Cancer, Vimal Patel, MD and Biren Saraiya
BRAF-Targeted Therapy in Metastatic Melanoma, Noori Kim and April C. Deng